S&P Healthcare 18,500.00 10.11%
  • Sun Pharmaceutical Industries Ltd. 0000.00
  • Divi’s Laboratories Ltd. 0000.00
  • Cipla Ltd. 0000.00
  • Torrent Pharmaceuticals Ltd. 0000.00
  • Dr. Reddy’s Laboratories Ltd. 0000.00
  • Zydus Lifesciences Ltd. 0000.00
  • Mankind Pharma Ltd. 0000.00
  • Lupin Ltd. 0000.00
  • Aurobindo Pharma Ltd. 0000.00
  • Alkem Laboratories Ltd. 0000.00
  • Glenmark Pharmaceuticals Ltd. 0000.00
  • Natco Pharma Ltd. 0000.00
  • Shilpa Medicare Ltd. 0000.00
  • Ajanta Pharma Ltd. 0000.00
  • J B Chemicals & Pharmaceuticals Ltd. 0000.00
  • Apollo Hospitals Enterprise Ltd. 0000.00
  • Fortis Healthcare Ltd. 0000.00
  • Max Healthcare Institute Ltd. 0000.00
  • Narayana Hrudayalaya Ltd. 0000.00
  • Shalby Ltd. 0000.00
  • Poly Medicure Ltd. 0000.00
  • Medi Assist India Ltd. 0000.00
  • ICICI Lombard General Insurance Company Ltd. 0000.00
  • HDFC Life Insurance Company Ltd. 0000.00
  • SBI Life Insurance Company Ltd. 0000.00
  • Bajaj Finserv Ltd. 0000.00
  • Metropolis Healthcare Ltd. 0000.00
  • Thyrocare Technologies Ltd. 0000.00

Odisha Receives Investment Commitments Worth ₹7,043 Cr in Pharma & Medtech

Odisha Receives Investment Commitments Worth ₹7,043 Cr in Pharma & Medtech

The investments are expected to strengthen Odisha’s pharma and medtech manufacturing base, create jobs, and reduce dependence on imports.

Odisha has received investment commitments worth ₹7,043 crore across the pharmaceutical and medical technology sectors, marking a major step in strengthening the state’s position as an emerging healthcare manufacturing hub.

The announcements were made during high-level industry interactions led by the state government, reflecting strong investor confidence in Odisha’s policy framework and industrial infrastructure.

The proposed investments cover pharmaceutical formulations, bulk drugs, medical devices, and allied healthcare manufacturing.

Chief Minister Mohan Charan Majhi said the inflow of investments underscores Odisha’s commitment to building a competitive and innovation-driven industrial ecosystem. “Odisha is focused on creating an enabling environment for pharma and medtech companies through robust infrastructure, transparent governance, and investor-friendly policies.”

Beyond manufacturing scale-up, the investments are expected to drive research, innovation, and technology transfer in the pharma and medtech sectors.

Industries Minister Sampad Chandra Swain highlighted that targeted incentives and sector-specific parks are helping attract long-term investments. “With dedicated industrial clusters and fast-track approvals, Odisha is positioning itself as a preferred destination for pharma and medical device manufacturing.”

He added that the government is working closely with investors to ensure timely project execution and seamless operational support.

Looking ahead, the Odisha government plans to convert these commitments into on-ground projects through continued industry engagement, reinforcing the state’s alignment with national initiatives such as Make in India and Atmanirbhar Bharat, while building a sustainable healthcare manufacturing ecosystem.

Stay tuned for more such updates on Digital Health News

Follow us

More Articles By This Author


Show All